Truway Health Launches Innovative In-Vitro Cryo-Therapeutic Clinical Study

Advancing Cellular Preservation, Precision Therapy, and Translational Science

Truway Health, Inc. is proud to announce the successful registration and public release of a new clinical research study through the National Institutes of Health (NIH) ClinicalTrials.gov Protocol Registration & Results System (PRS).

Study Title

Evaluation of In-Vitro Cryo-Therapeutic Protocols on Human Cell Samples (TWH-CRYO-001)

This study represents a major milestone in Truway Health’s ongoing commitment to advancing next-generation therapeutic science, laboratory precision, and evidence-based innovation.

? About the Study

The TWH-CRYO-001 protocol is an early-phase, non-ACT (Applicable Clinical Trial) laboratory study designed to evaluate cryo-therapeutic protocols applied to human cell samples in vitro.

Rather than testing treatments directly in patients, this research focuses on controlled laboratory environments to better understand:

• Cellular response to cryo-therapeutic exposure

• Structural and functional preservation at ultra-low temperatures

• Protocol optimization for safety, repeatability, and translational readiness

• Potential implications for regenerative medicine, oncology, and cellular therapies

By studying cryo-therapeutic effects at the cellular level, Truway Health aims to generate high-quality data that can inform future clinical applications and regulatory pathways.

? Why Cryo-Therapeutics Matter

Cryo-therapeutic technologies are increasingly relevant across multiple medical and scientific domains, including:

• Cellular preservation & viability

• Targeted destruction of diseased cells

• Regenerative medicine & tissue engineering

• Advanced laboratory research & biobanking

• Precision oncology and therapeutic delivery research

This study contributes to the foundational science required to responsibly translate cryo-based approaches into future therapeutic solutions.

? Regulatory & Transparency Commitment

In alignment with Truway Health’s compliance-first philosophy, this study has been:

• Registered with NIH ClinicalTrials.gov

• Reviewed and released through the PRS system

• Designated as Non-ACT (Early Phase 1 research)

• Publicly available to ensure transparency, reproducibility, and accountability

Key registration details include:

• Unique Protocol ID: TWH-CRYO-IVT-001

• NCT Number: NCT07321028

• Initial Public Release: December 10, 2025

• Last Update: December 22, 2025

This ensures that researchers, collaborators, and regulatory bodies can independently review the study framework and objectives.

? Advancing Truway Health’s Research Mission

TWH-CRYO-001 reflects Truway Health’s broader mission to:

• Build regulatory-ready research infrastructure

• Bridge laboratory science and clinical translation

• Support innovative therapies through rigorous data

• Maintain leadership in ethical, compliant medical research

This study also complements Truway Health’s expanding portfolio across diagnostics, laboratory services, and advanced therapeutic research.

? Learn More

The full clinical trial record is publicly accessible via ClinicalTrials.gov, providing detailed protocol information and study status for interested researchers and partners.

For collaboration inquiries, research partnerships, or institutional engagement, please contact Truway Health directly through our website.

Truway Health, Inc.
Innovating responsibly. Advancing medicine with integrity.